Combined aortic and mitral valve replacement with the convexo-concave Björk-Shiley prosthesis yielded 5% in-hospital mortality, 79% clinical improvement, and a 5.9% annual thrombo-embolic rate.
Observational (n=39)
What are the early clinical and hemodynamic outcomes of combined aortic and mitral valve replacement with the convexo-concave Björk-Shiley prosthesis?
Combined aortic and mitral valve replacement with the convexo-concave Björk-Shiley prosthesis provides clinical and hemodynamic improvement with an acceptable early complication rate.
This paper reports the early results of combined aortic and mitral valve replacement in 39 patients, who underwent operation with the convexo-concave Björk-Shiley prosthesis. There were no intra-operative deaths. Two patients (5%) died while in hospital of myocardial failure and left ventricular rupture, respectively. One late death (3%) was due to a thrombosis of the mitral prosthesis (N.Y.H.A. class IV at operation). Cumulative follow-up (2-31 months) was 100%. One patient had radial artery embolization while converting to atrial fibrillation. Another patient required repair of an aortic paraprosthetic leakage. Clinical improvement (N.Y.H.A.) was noted in 15/19 re-examined patients (79%). Average heart volume decreased (p less than 0.05) and Maximal working capacity increased (p less than 0.05) after valve replacement. Seven patients (7/19) converted to sinus rhythm after operations and one (1/19) developed atrial arrhythmia. Haemolysis was generally mild and without signs of anaemia. The overall thrombo-embolic rate (5.9% per year) remained thus far the same as that encountered with the standard model prosthesis in combined aortic and mitral valvular disease.
Bengt Åberg (Thu,) conducted a observational in combined aortic and mitral valvular disease (n=39). Combined aortic and mitral valve replacement with the convexo-concave Björk-Shiley prosthesis was evaluated on clinical improvement (N.Y.H.A.). Combined aortic and mitral valve replacement with the convexo-concave Björk-Shiley prosthesis yielded 5% in-hospital mortality, 79% clinical improvement, and a 5.9% annual thrombo-embolic rate.